NAVAL DAVER to Tumor Microenvironment
This is a "connection" page, showing publications NAVAL DAVER has written about Tumor Microenvironment.
Connection Strength
0.372
-
TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Biology, Current Therapy, and Future Directions. Cancer Discov. 2022 11 02; 12(11):2516-2529.
Score: 0.096
-
Checkpoint Inhibitors and Other Immune-Based Therapies in Acute Myeloid Leukemia. Cancer J. 2022 Jan-Feb 01; 28(1):43-50.
Score: 0.091
-
Harnessing the Immune System Against Leukemia: Monoclonal Antibodies and Checkpoint Strategies for AML. Adv Exp Med Biol. 2017; 995:73-95.
Score: 0.064
-
Single-Cell CD4 and CD8 T-Cell Secretome Profiling Reveals Temporal and Niche Differences in Acute Myeloid Leukemia Following Immune Checkpoint Blockade Therapy. Cancer Res Commun. 2024 03 06; 4(3):671-681.
Score: 0.026
-
Paired single-B-cell transcriptomics and receptor sequencing reveal activation states and clonal signatures that characterize B cells in acute myeloid leukemia. J Immunother Cancer. 2024 Feb 28; 12(2).
Score: 0.026
-
Comprehensive characterization of IFN? signaling in acute myeloid leukemia reveals prognostic and therapeutic strategies. Nat Commun. 2024 Feb 28; 15(1):1821.
Score: 0.026
-
Resistance to targeted therapies: delving into FLT3 and IDH. Blood Cancer J. 2022 06 09; 12(6):91.
Score: 0.023
-
Role of MSC-derived galectin 3 in the AML microenvironment. Biochim Biophys Acta Mol Cell Res. 2018 07; 1865(7):959-969.
Score: 0.018